Model: rprav007/snowflake-arctic-embed-m-finetuned-v1
Author: rprav007
Pipeline: sentence-similarity
Library: sentence-transformers
Tags: sentence-transformers, safetensors, bert, sentence-similarity, feature-extraction, generated_from_trainer, dataset_size:515, loss:MatryoshkaLoss, loss:MultipleNegativesRankingLoss, arxiv:1908.10084, arxiv:2205.13147, arxiv:1705.00652, base_model:Snowflake/snowflake-arctic-embed-m, base_model:finetune:Snowflake/snowflake-arctic-embed-m, model-index, text-embeddings-inference, endpoints_compatible, region:us
Base models (finetune): id: Snowflake/snowflake-arctic-embed-m
Card metadata: tags: sentence-transformers, sentence-similarity, feature-extraction, generated_from_trainer, dataset_size:515, loss:MatryoshkaLoss, loss:MultipleNegativesRankingLoss
base_model: Snowflake/snowflake-arctic-embed-m
widget: source_sentence: What challenges do providers in other settings face when delivering intensive lifestyle interventions?
sentences: 2002 JAMA November28,2023 Volume330,Number20 (Reprinted) jama.com
© 2023 American Medical Association. All rights reserved.
Downloaded from jamanetwork.com by Rockefeller University user on 02/22/2025, Providers in other settings often lack the time and training to deliver intensive lifestyle 
interventions. This treatment also can be time-consuming and costly for participants, and 
many individuals, including those in rural communities and economically disadvantaged 
urban areas, do not have access to care. Identifying methods to disseminate effective lifestyle 
modification to the millions of people who would benefit from it is thus a key priority. These 
efforts have evaluated delivering treatment in different settings and using new modalities.
Primary Care Practice
Primary care clinicians have been encouraged by the USPSTF and the Centers for Medicare, intak e and cause leanness (162, 163). In seminal s tudies sugges ting
tha t signals fr om adipose tissue r egula te appetite, Herv e y sho w ed
tha t obese r a ts with VMH lesions pla ced in par abiotic union with
normal r a ts o v erpr oduce an appetite-suppr essing fa ctor. In par abi-
osis e xperiments, surgical union leads to an e xchange of blood
betw een two animals, allo wing one to determine whether cir cula t-
ing fa ctors e xert effects on animals e xposed to it. In this case, the
VMH-lesioned animal o v erpr oduced an appetite-suppr essing
fa ctor tha t normal but not lesioned animals w er e capable of r e-
sponding to. These da ta sugges ted tha t neur ons in the v entr omedial, source_sentence: What are the dosage forms and routes of administration for Semaglutide mentioned in the context?
sentences: • Semaglutide(0.25-2.4mg/wksubcutaneously)• Phentermine-topiramateER(3.75/23mg/dto15/92mg/dorally)• Liraglutide(0.6-3mg/dsubcutaneously)• Naltrexone-bupropionER(8mg/90mgdailyto16mg/180mgtwice
dailyorally)
• Orlistat(60-120mg3timesdailyorally)
• FDAapprovedforshort-termuse
• Diethylpropion(IR:25mg3timesdaily;ER:75mg/dorally)• Phentermine(8mg/dto8mg3timesdailyor15-37.5mg/dorally)
• Commonlyusedofflabel
• Tirzepatide(2.5-15mg/wksubcutaneously)• Semaglutide(3-50mg/dorally)(50-mg/doraldosenotyetavailable)• Topiramate(12.5-200mg/din1to2divideddoses)• Semaglutide(0.25-2.0mg/wksubcutaneously)• Liraglutide(0.6-1.8mg/dsubcutaneously)• Bupropion(SR:100-200mgtwicedailyorally;ER:150-450mg/dorally)• Metformin(500-2500mg/dorally)
5%(naltrexone-, a reduced-calorie diet, appropriate for a reduced body weight, individuals should engage in 
high levels of physical activity (200–300 minutes/week). Multiple trials have shown that 
higher levels of physical activity are associated with larger long-term weight losses (Jakicic 
et al., 2018; Jeffery, Wing, Sherwood, & Tate, 2003). Increased physical activity is likely 
necessary to compensate for the increased energy efficiency that accompanies weight loss 
(Rosenbaum & Leibel 2016). Regular self-monitoring of body weight is also critical. The 
National Weight Control Registry – which follows individuals who have maintained a loss 
≥13.6 kg (30 lb) for at least 1 year – found that frequent (weekly or more) weighing was, the firs t GIPR/GLP-1R dual agonis t (150) confirmed a s ynergis tic
inter a ction yielding both metabolic benefits and w eight loss in
r odent and prima te models tha t w ent w ell be y ond the effects of a
GLP-1 mono-agonis t. Initial clinical s tudies confirmed its pr ofound
w eight-r educing and antidiabetic effects (96), and in 2022, a r efined
v ersion of this molecule class, tirzepa tide, w as appr o v ed for the
tr ea tment of diabetes (87, 151). Tirzepa tide is a r epr esenta tiv e of
the GIP/GLP-1R co-agonis t class fa v oring GIP o v er GLP-1 a ction
in a 5:1 r a tio. Clinical s tudies ha v e sho wn tha t tirzepa tide induces
an a v er age of 21.5% w eight loss in humans with obesity , with 15%, source_sentence: What was the focus of the study conducted by S Heymsfield and colleagues regarding recombinant leptin?
sentences: (127). It w as named gh-r elin because it w as originally isola ted as a
ligand for the gr o wth hormone–r eleasing fa ctor. Shortly ther ea fter,
it w as disco v er ed tha t ghr elin can s timula te appetite and antagonize
leptin’s effects on anor e xigenic neur ons in the ar cua te nucleus of the
SCIENCE TRANSLA TIONAL MEDICINE
|
REVIEW
Tschöp and Friedman, Sci. T r ansl. Med. 15, eadh4453 (2023) 22 No v ember 2023 6 of 21
Downloaded from https://www.science.org at Rockefeller University on January 02, 2024, logical r esponse to long-term peripher al and centra l leptin infusion in lean and obese
mice. Pr oc. Na tl. Acad. Sci. U.S.A. 94, 8878–8883 (1997).
183. S. He ymsfield, A. Gr eenberg, K. F ujioka, R. Dixon, R. Kushner, T . Hunt, J. Lubina, J. Pa tane,
B. Self, P . Hunt, M. McCamish, R ecombinant leptin for w eight loss in obese and lean
adults. JAMA 282, 1568–1575 (1999).
184. E. A. Or al, V . Simha, V . Ruiz, A. Andew elt, A. Pr emkumar, P . Snell, A. J. W agner, A. M. DeP aoli,
M. L. R eitman, S. I. Ta ylor, P . Gordon, A. Garg, Leptin-re pla cement ther apy for lipody s-
tr ophy . N. Engl. J. Med. 346, 570–578 (2002).
185. S. H. Chou, J. P . Chamberland, X. Liu, G. Ma tar ese, C. Gao, R. Stefanakis, M. T . Brink oetter,, prescription). If participants’ weight losses fell outside of the expected range, they were 
prompted to select a behavioral strategy (e.g., use portion-controlled foods) to get back on 
track. They also received at least weekly feedback on their progress, delivered by a trained 
interventionist, by phone, email, or app. Intervention participants in this12-week pilot study 
lost 9.4 kg compared to 0.6 kg in the control group.
Other researchers have combined enhanced digital interventions with low-intensity provider 
contact and tested whether these combined interventions benefit socioeconomically 
disadvantaged patients, who have suboptimal weight loss in most programs. In a recent, source_sentence: What role does the adipocyte hormone leptin play in neural activity related to brain reward centers?
sentences: liraglutide and the combination therapies have the largest effects. Adding weight loss 
medication to high-intensity lifestyle modification substantially increases initial weight 
reduction, compared with lifestyle counseling alone, satisfying many patients’ desires for 
larger losses (Wadden et al., 2005; Wadden et al., 2019). Medications, however, could play 
an even more important role in obesity management by facilitating the maintenance of lost 
weight, potentially by counteracting previously described unfavorable changes in appetite-
related hormones and energy expenditure that occur with weight loss (Apovian et al., 2015; 
Rosenbaum & Leibel, 2016). From this perspective, patients would take anti-obesity, consuming 50 gr ams of sucr ose compar ed with tha t the y e xperi-
enced when the y w er e a t their s table w eight (6). In another s tudy ,
adminis tr a tion of the adipocyte hormone leptin alter ed neur al a c-
tivity in br ain r e w ard centers (7). These s tudies dir ectly sho w tha t
signals r eporting an individual’s nutritional s ta te influence the sub-
jectiv e r esponse to a nutrient.
In 1969, Herv e y formally pos tula ted tha t appetite is r egula ted by
feedba ck mechanisms in which contr ol centers in the br ain ar e r eg-
ula ted by a variety of signals fr om the gas tr ointes tinal tr a ct, adipose
tissue, and else wher e (8). Signals r eflecting the aggr ega te size of fa t, 27. C. Clemmensen, T . D. Muller, S. C. W oods, H. R. Berthoud, R. J. Seeley , M. H. Tschop, Gut-
br ain cr oss-talk in metabolic contr ol. C ell 168, 758–774 (2017).
28. T . D. Muller, M. Bluher, M. H. Tschop, R. D. DiMar chi, Anti-obesity drug disco v ery: Ad-
vances and challenges. Na t. Rev . Drug Disco v. 21, 201–223 (2022).
29. V . L. Albaugh, Y . He, H. Munzberg, C. D. Morrison, S. Yu, H. R. Berthoud, R egula tion of body
w eight: Lessons learned from baria tric surgery . Mol. Metab. 68, 101517 (2023).
SCIENCE TRANSLA TIONAL MEDICINE
|
REVIEW
Tschöp and Friedman, Sci. T r ansl. Med. 15, eadh4453 (2023) 22 No v ember 2023 15 of 21
Downloaded from https://www.science.org at Rockefeller University on January 02, 2024, source_sentence: What techniques do participants use to address maladaptive thinking in behavioral treatment for obesity?
sentences: Randomized trial of lifestyle modification and pharmacotherapy for obesity. New England Journal 
of Medicine, 353(20), 2111–2120. [PubMed: 16291981] 
Wadden TA, Neiberg RH, Wing RR, Clark JM, Delahanty LM, Hill JO, … Look AHEAD Research 
Group. (2011). Four-year weight losses in the look AHEAD study: Factors associated with long-
term success. Obesity, 19(10), 1987–1998. [PubMed: 21779086] 
Wadden TA, Tsai AG, & Tronieri JS (in press). A protocol to deliver intensive behavioral therapy 
(IBT) for obesity in primary care settings: The MODEL-IBT Program. Obesity, in press.
Wadden et al. Page 21
Am Psychol. Author manuscript; available in PMC 2021 February 01.
Author Manuscript Author Manuscript Author Manuscript Author Manuscript, leptin pr ev ents w eight gain and tha t a phy siologic incr ease a cts to
r eturn w eight to the s tarting point (182). Ho w ev er, despite r educing
body w eight and fa t mass, phy siologic incr eases of leptin concentr a-
tion in fed animals do not alter these other phy siologic s y s tems
(182). C onsis tent with its r eduction of w eight in lean animals,
leptin tr ea tment of non-obese pa tients, including those with lo w
baseline concentr a tions of the hormone, also r educes food intak e
and body w eight (183–187). ob/ob mice ea t larger meals, indica tiv e
of r educed sa tiety , sugges ting tha t leptin a cts a t leas t in part by mod-
ula ting the short-term s y s tem (188, 189). Ov er all, changes in leptin, Participants practice stimulus control by altering eating- and activity-related cues in their 
environment and use cognitive techniques to address maladaptive thinking. Behavioral 
treatment also may incorporate motivational interviewing to support an individual’s 
commitment to change, as well as acceptance-based approaches to improve long-term 
adherence (Butryn, Schumacher, & Forman, 2018). One of the greatest challenges to 
behavioral treatment is identifying the specific eating, activity, cognitive, and emotional 
factors that contribute to an individual’s obesity and then focusing specifically on these 
targets. Too often, particularly with group treatment, all individuals receive the same
pipeline_tag: sentence-similarity
library_name: sentence-transformers
metrics: cosine_accuracy@1, cosine_accuracy@3, cosine_accuracy@5, cosine_accuracy@10, cosine_precision@1, cosine_precision@3, cosine_precision@5, cosine_precision@10, cosine_recall@1, cosine_recall@3, cosine_recall@5, cosine_recall@10, cosine_ndcg@10, cosine_mrr@10, cosine_map@100
model-index: name: SentenceTransformer based on Snowflake/snowflake-arctic-embed-m
results: task: type: information-retrieval
name: Information Retrieval
dataset: name: Unknown
type: unknown
metrics: type: cosine_accuracy@1
value: 0.9166666666666666
name: Cosine Accuracy@1
verified: no, type: cosine_accuracy@3
value: 0.9166666666666666
name: Cosine Accuracy@3
verified: no, type: cosine_accuracy@5
value: 1
name: Cosine Accuracy@5
verified: no, type: cosine_accuracy@10
value: 1
name: Cosine Accuracy@10
verified: no, type: cosine_precision@1
value: 0.9166666666666666
name: Cosine Precision@1
verified: no, type: cosine_precision@3
value: 0.3055555555555556
name: Cosine Precision@3
verified: no, type: cosine_precision@5
value: 0.20000000000000004
name: Cosine Precision@5
verified: no, type: cosine_precision@10
value: 0.10000000000000002
name: Cosine Precision@10
verified: no, type: cosine_recall@1
value: 0.9166666666666666
name: Cosine Recall@1
verified: no, type: cosine_recall@3
value: 0.9166666666666666
name: Cosine Recall@3
verified: no, type: cosine_recall@5
value: 1
name: Cosine Recall@5
verified: no, type: cosine_recall@10
value: 1
name: Cosine Recall@10
verified: no, type: cosine_ndcg@10
value: 0.9525563798394495
name: Cosine Ndcg@10
verified: no, type: cosine_mrr@10
value: 0.9375
name: Cosine Mrr@10
verified: no, type: cosine_map@100
value: 0.9375
name: Cosine Map@100
verified: no
Likes: 0 | All-time downloads: 6
Created: 2025-02-27 04:52:58